The negotiations took place during a two-week meeting of the Intergovernmental Working Group (IGWG), which is responsible for developing the annex under the WHO Pandemic Agreement.

SWITZERLAND—WHO Member States have advanced negotiations on the World Health Organization (WHO) Pathogen Access and Benefit-Sharing (PABS) Annex in Switzerland in November 2026, reaffirming their commitment to finalizing the framework for consideration by the World Health Assembly in May 2027.
The proposed system aims to accelerate the sharing of pathogens with pandemic potential and their genetic sequence data while ensuring equitable access to vaccines, diagnostics, and therapeutics developed from them.
The negotiations took place during a two-week meeting of the Intergovernmental Working Group (IGWG), which is responsible for developing the annex under the WHO Pandemic Agreement.
Discussions focused on establishing a legally binding framework that balances access to biological materials and information with fair distribution of the resulting health products.
Negotiations advance benefit-sharing framework
Member States made progress on provisions governing benefit-sharing, clarifying the responsibilities of participating partners and examining how the proposed system could improve access to pandemic-related medical products.
They also advanced discussions on sharing pathogens with pandemic potential, including biological materials and genetic sequence information.
Further deliberations examined the role of laboratories and other technical partners in facilitating the collection, handling and exchange of these resources.
Ambassador Tovar da Silva Nunes of Brazil, co-chair of the IGWG Bureau, said negotiations had advanced both benefit-sharing and access provisions.
Delegates had worked constructively to develop a practical and equitable framework capable of delivering public health benefits when pandemic threats emerge, he noted.
His French counterpart, Ambassador Anne-Claire Amprou, also highlighted progress through formal and informal discussions.
She said Member States had demonstrated a commitment to finding common ground and refining the annex ahead of the May 2027 deadline.
Throughout the meeting, WHO experts provided scientific, legal and operational guidance to help delegates address complex technical and policy issues.
Industry implications and next steps
The proposed PABS system has significant implications for pharmaceutical manufacturers, biotechnology companies, diagnostic developers, research institutions, and vaccine producers.
Its provisions will shape how these stakeholders access pathogen samples and genetic sequence data, as well as their obligations to share benefits arising from the development of pandemic-related products.
A predictable framework could support research and development by improving access to biological resources while establishing clearer expectations for collaboration, product distribution and benefit-sharing.
However, the final arrangements will also influence how manufacturers manage supply commitments, production capacity and access to products during future public health emergencies.
At the meeting’s close, WHO Director-General Dr. Tedros Adhanom Ghebreyesus acknowledged the progress made and urged member states to translate their commitments into an agreed text.
He expressed confidence in the delegations’ commitment to meeting the May 2027 deadline, while calling for faster progress towards resolving outstanding issues.
Member States agreed to maintain momentum through informal consultations aimed at narrowing differences before the next formal negotiations.
The IGWG will resume discussions on 11 to 15 January 2027, followed by further sessions on 15 to 19 February and 15 to 25 March.
The World Health Assembly adopted the WHO Pandemic Agreement in May 2025 to strengthen international cooperation in pandemic prevention, preparedness and response.
It also established the IGWG to advance implementation of the agreement, including the development and negotiation of the PABS Annex.
Be the first to leave a comment